Doripenem

Drug Profile

Doripenem

Alternative Names: Doribax; Doripenem hydrate; Finibax IV Solution; S-4661

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Shionogi
  • Developer Janssen Research & Development; Ortho-McNeil; Shionogi
  • Class Antibacterials; Carbapenems; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Nosocomial pneumonia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gram-negative infections; Gram-positive infections; Intra-abdominal infections; Meningococcal infections; Nosocomial pneumonia; Paediatric infections; Respiratory tract infections; Urinary tract infections
  • Discontinued Bacterial infections; Pneumonia

Most Recent Events

  • 12 Aug 2013 Discontinued - Phase-III for Nosocomial pneumonia in Australia, Canada, Guatemala, India, Israel, Mexico, Philippines, Russia, South Africa,Thailand, Turkey and Ukraine (IV)
  • 31 Jul 2013 Phase-III clinical trials in Intra-abdominal infections (in children and adolescents) in India prior to July 2013 (IV)
  • 30 Jun 2013 Janssen terminates phase III trial in Intra-abdominal infections (in children and adolescents) in the USA, Panama, Argentina, Brazil, Chile, Colombia, India, Latvia and Lithuania (NCT01110382)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top